While mutations in the COMP gene are associated with two forms of skeletal dysplasia—pseudoachondroplasia and multiple epiphyseal dysplasia—altered expression and/or systemic release of wild type COMP has been described in a number of predominantly age-dependent and degenerative diseases such as osteoarthritis, cardiomyopathy, fibrosis as well as breast and prostate cancers [13,15]. This evidence concerns the gene COMP and prostate carcinoma.